The effect of combined mitoxantrone and methylprednisolone therapy in primary and secondary progressive multiple sclerosis;Kombinierte mitoxantron-/methylprednisolon-behandlung bei primär und sekundär chronisch progredienter multipler sklerose. Eine anwendungsbeobachtung bei 65 patienten

Nervenarzt

Volumn 76, Issue 6, 2005, Pages 740-747

  Zingler, V C ^a,b   Strupp, M ^a   Jahn, K ^a   Gross A ^a   Hohlfeld, R ^a   Brandt, T ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Cardiotoxicity; Methylprednisolone; Mitoxantrone; Primary progressive multiple sclerosis; Secondary progressive multiple sclerosis

Indexed keywords

METHYLPREDNISOLONE; MITOXANTRONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RELAPSE; SAMPLE SIZE; TREATMENT OUTCOME;

ADULT; AGED; ANALGESICS; DISEASE PROGRESSION; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; PROGNOSIS; RECOVERY OF FUNCTION; RECURRENCE; TREATMENT OUTCOME;

EID: 21644479602     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-005-1885-x     Document Type: Article

References (27)

1. Thompson AJ, Polman CH, Miller DH et al. (1997) Primary progressive multiple sclerosis. Brain 120:1085-1096
2. Ingle GT, Stevenson VL, Miller DH et al. (2003) Primary progressive multiple sclerosis: a 5-year clinical and MR-study. Brain 126:1-19
3. Cottrell DA, Kremenchutzky M, Rice GP et al. (1999) Natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122:625-639
4. Ebers G (1998) Natural history of multiple sclerosis. In: Compston A, Ebers G, Lassmann H et al. (eds) McAlpine's multiple sclerosis, 3rd edn. Churchill Livingstone, London, pp 437-498
5. Hartung HP, Gonsette R, König N et al. (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018-2025
6. Edan G, Miller D, Clanet M et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 62:112-118
7. Gonsette RE, Demonty L (1990) Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology 40 [Suppl 1]:261
8. Krapf H, Mauch E, Fetzer U et al. (1995) Serial gadolinium enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology 37:113-119
9. Kappos L, Gold R, Künstler E et al. (1990) Mitoxantrone in the treatment of rapidly progressive MS: a pilot study with serial gadolinium-enhanced MRI. Neurology 40 [Suppl 1]:261
10. Noseworthy JH, Hopkins MB, Vandervoort MK et al. (1993) An open trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology 43:1401-1406
11. Goodin DS, Arnason BG, Coyle PK et al. (2003) The use of mitoxantrone (novantrone) for the treatment of multiple sclerosis. Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 61:1332-1338
12. Poser CM, Paty DW, Scheinberg L et al. (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
13. McDonald WI, Compston A, Edan G et al. (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
14. Kurtzke JF (1983) Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33:1444-1452
15. Voltz R, Starck M, Zingler VC et al. (2004) Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 10:472-474
16. Ghalie RG, Edan G, Laurent M et al. (2002) Cardiac adverse effects associated with mitoxantrone (novantrone) therapy in patients with MS. Neurology 59:909-913
17. Edan G, Brochet B, Clanet M et al. (2001) Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients. Mult Scler 7[ Suppl 1]:14
18. Hartung HP, Gonsette R, Morrissey S et al. (1999) In: Rudick RA, Goodkin DE (eds) Multiple sclerosis therapeutics. Martin Dunitz, London, p 335-348
19. Mauch E, Eisenmann S, Hahn A et al. (1999) Mitoxantrone in the treatment of patients with multiple sclerosis (MS): a large single center experience. American Neurological Association, Abstract
20. Mauch E, Kornhuber HH, Krapf H et al. (1992) Treatment of multiple sclerosis with mitoxantrone. Eur Arch Psychiatry Clin Neurosci 242:96-102
21. Millefiorini E, Gasperini C, Pozzilli C et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-months clinical and MRI outcome. J Neurol 244:153-159
22. Gonsette RE (2003) Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 206:203-208
23. Pai VB, Nahata MC (2000) Cardiotoxicity of chemotherapeutic agents. Incidence, treatment and prevention. Drug Saf 22:263-302
24. Zephir H, de Seze J, Duhamel A et al. (2004) Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients. J Neurol Sci 218:73-77
25. Currier RD, Haerer AF, Meydrech EF (1993) Low dose oral methotrexate on multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 56:1217-1218
26. Yudkin PL, Ellison GW, Ghezzi A et al. (1993) Overview of azathioprine therapy in multiple sclerosis. Lancet 338:1051-1055
27. Stevenson VL, Miller DH, Rovaris M et al. (1999) Primary and transitional progressive MS: a clinical and MRI cross-sectional study. Neurology 52:839-845